TAA06 injection
T-cell malignancies (specific type not specified)
Phase 1Active (first patient dosed April 2023)
Key Facts
Indication
T-cell malignancies (specific type not specified)
Phase
Phase 1
Status
Active (first patient dosed April 2023)
Company
About PersonGen BioTherapeutics
A Chinese biotech company developing next-generation CAR-T and allogeneic cellular therapies for T-cell cancers and autoimmune diseases.
View full company profile